TLS data


Corporate Newsletter

Site head Dr. Wolfgang Glaesner, Chief Science Officer of Lilly explained complexities and challenges of drug development to assemblymembers.

Assembly Select Committee on Biotech & Biocom Convene Briefing at Lilly Biotechnology Center

  • Fri Nov 09 19:23:00 GMT 2018
  • San Diego
  • Author Jimmy Jackson

On October 11th, Biocom was pleased to join with Assembly Speaker pro Tempore Kevin Mullin in welcoming the Assembly Select Committee on Biotechnology to the Lilly Biotechnology Center, Campus Point (San Diego), for an educational briefing and tour.

Assemblyman Mullin was joined for the briefing by Assembly Majority Whip Todd Gloria (who represents the Lilly site), Assemblymember Autumn Burke (Chair, Assembly Revenue and Taxation Committee and member of the Assembly Health Committee), Assemblymember Randy Voepel, and Senator Ben Hueso (Chair of the Latino Caucus).  Jason Weisz of State Senate President pro Tempore Toni Atkins’ (who also represents the site) office was also in attendance, as were representatives of fellow life science trade associations AdvaMed and CLSA. 

Participants were welcomed by site head (and Biocom board member) Dr. Wolfgang Glaesner, Chief Science Officer, Lilly, and walked through the complexities of drug development and the use of technology to accelerate it by Dr. Andrew Korytko and Dr. Devon Thompson.  A robust and candid conversation about drug discovery and its challenges with the legislators in attendance followed.

Participants were then treated to a tour of the facility, which finished a major expansion last year that more than doubled its size to 180,000 square feet, A highlight was its unique remote drug design and testing studio.  According to a 2017 release, “The Lilly Life Science Studio will allow researchers across the globe to remotely design, synthesize and screen investigational molecules in an unprecedented manner.”

Biocom thanks the Lilly Biotechnology Center for being such gracious hosts for the committee, Assemblyman Kevin Mullin for bringing the briefing together, and to the legislators who took time out of their very busy schedules to learn more about the biotechnology industry.


Stay in the know with the Biocommunique

Sign up for Biocom's monthly newsletter to get all the latest life science news sent directly to your inbox.


Related Articles View All  
Proposed program would promote development and appropriate use of consensus standards to help expedite pharmaceutical development.  
The program offers corporate income tax credits for companies interested in relocating to or growing in California.  
Melanie Cohn, Director of Regional Policy and Government Affairs, discussed East Bay's vibrancy and Biocom's plans for future growth.  
Included in the bills is AB 1468, a $100 million tax on opioid manufacturers as well as consumer privacy measures.